Vimarsana
Biggest News Aggregation in the World

Longitudinal Evaluation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Longitudinal Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Longitudinal Evaluation Today - Breaking & Trending Today

Wrist Device That Monitors Activity Could Help Provide Early Warning of Alzheimer's - Vimarsana News

Wrist Device That Monitors Activity Could Help Provide Early Warning of Alzheimer's

Monitoring daily activity patterns using a wrist-worn device may detect early warning signs of Alzheimer’s disease, according to a new study led by researcher

Wristwatch-like devices detect early signs of Alzheimer's - Vimarsana News

Wristwatch-like devices detect early signs of Alzheimer's

Monitoring daily activity patterns using a wrist-worn device may detect early warning signs of Alzheimer's disease, according to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health.

Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting - Exagen (NASDAQ:XGN) - Vimarsana News

Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting - Exagen (NASDAQ:XGN)

SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of

Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting - Vimarsana News

Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting

SAN DIEGO, California, Sept. 28, 2023 -- Exagen Inc. , a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of...

Low Amyloid Burden Bodes Well for Future Dementia Risk - Vimarsana News

Low Amyloid Burden Bodes Well for Future Dementia Risk

A ray of hope amidst disappointing results from A4 trial